Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14355-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#14355-1-AP, RRID:AB_2194422
- Product name
- ST6GAL1 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated ST6GAL1 antibody (Cat. #14355-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: FC, IHC, IP, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Ellagic acid alleviates TNBS-induced intestinal barrier dysfunction by regulating mucin secretion and maintaining tight junction integrity in rats.
ST6GALNAC1 promotes the invasion and migration of breast cancer cells via the EMT pathway.
Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma.
Downregulation of ST6GAL1 Promotes Liver Inflammation and Predicts Adverse Prognosis in Hepatocellular Carcinoma.
Long noncoding RNA TINCR facilitates hepatocellular carcinoma progression and dampens chemosensitivity to oxaliplatin by regulating the miR-195-3p/ST6GAL1/NF-κB pathway.
Integrated Systems Analysis of the Murine and Human Pancreatic Cancer Glycomes Reveals a Tumor-Promoting Role for ST6GAL1.
High-Risk HPV16 E6 Activates the cGMP/PKG Pathway Through Glycosyltransferase ST6GAL1 in Cervical Cancer Cells.
Caveolin-1 facilitates cell migration by upregulating nuclear receptor 4A2/retinoid X receptor α-mediated β-galactoside α2,6-sialyltransferase I expression in human hepatocarcinoma cells.
α1,6-Fucosyltransferase (FUT8) regulates the cancer-promoting capacity of cancer-associated fibroblasts (CAFs) by modifying EGFR core fucosylation (CF) in non-small cell lung cancer (NSCLC).
Alginate oligosaccharide attenuates α2,6-sialylation modification to inhibit prostate cancer cell growth via the Hippo/YAP pathway.
Modification of α2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway.
Peng B, Xue L, Yu Q, Zhong T
International journal of food sciences and nutrition 2023;74(4):476-486
International journal of food sciences and nutrition 2023;74(4):476-486
ST6GALNAC1 promotes the invasion and migration of breast cancer cells via the EMT pathway.
Luo Y, Cao H, Lei C, Liu J
Genes & genomics 2023 Nov;45(11):1367-1376
Genes & genomics 2023 Nov;45(11):1367-1376
Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma.
Wu RQ, Lao XM, Chen DP, Qin H, Mu M, Cao WJ, Deng J, Wan CC, Zhan WY, Wang JC, Xu L, Chen MS, Gao Q, Zheng L, Wei Y, Kuang DM
Immunity 2023 Jan 10;56(1):180-192.e11
Immunity 2023 Jan 10;56(1):180-192.e11
Downregulation of ST6GAL1 Promotes Liver Inflammation and Predicts Adverse Prognosis in Hepatocellular Carcinoma.
Liu R, Cao X, Liang Y, Li X, Jin Q, Li Y, Du H, Zao X, Ye Y
Journal of inflammation research 2022;15:5801-5814
Journal of inflammation research 2022;15:5801-5814
Long noncoding RNA TINCR facilitates hepatocellular carcinoma progression and dampens chemosensitivity to oxaliplatin by regulating the miR-195-3p/ST6GAL1/NF-κB pathway.
Mei J, Lin W, Li S, Tang Y, Ye Z, Lu L, Wen Y, Kan A, Zou J, Yu C, Wei W, Guo R
Journal of experimental & clinical cancer research : CR 2022 Jan 3;41(1):5
Journal of experimental & clinical cancer research : CR 2022 Jan 3;41(1):5
Integrated Systems Analysis of the Murine and Human Pancreatic Cancer Glycomes Reveals a Tumor-Promoting Role for ST6GAL1.
Kurz E, Chen S, Vucic E, Baptiste G, Loomis C, Agrawal P, Hajdu C, Bar-Sagi D, Mahal LK
Molecular & cellular proteomics : MCP 2021;20:100160
Molecular & cellular proteomics : MCP 2021;20:100160
High-Risk HPV16 E6 Activates the cGMP/PKG Pathway Through Glycosyltransferase ST6GAL1 in Cervical Cancer Cells.
Wang J, Liu G, Liu M, Cai Q, Yao C, Chen H, Song N, Yuan C, Tan D, Hu Y, Xiang Y, Xiang T
Frontiers in oncology 2021;11:716246
Frontiers in oncology 2021;11:716246
Caveolin-1 facilitates cell migration by upregulating nuclear receptor 4A2/retinoid X receptor α-mediated β-galactoside α2,6-sialyltransferase I expression in human hepatocarcinoma cells.
Chen X, Wang L, Yu X, Wang S, Zhang J
The international journal of biochemistry & cell biology 2021 Aug;137:106027
The international journal of biochemistry & cell biology 2021 Aug;137:106027
α1,6-Fucosyltransferase (FUT8) regulates the cancer-promoting capacity of cancer-associated fibroblasts (CAFs) by modifying EGFR core fucosylation (CF) in non-small cell lung cancer (NSCLC).
Li F, Zhao S, Cui Y, Guo T, Qiang J, Xie Q, Yu W, Guo W, Deng W, Gu C, Wu T
American journal of cancer research 2020;10(3):816-837
American journal of cancer research 2020;10(3):816-837
Alginate oligosaccharide attenuates α2,6-sialylation modification to inhibit prostate cancer cell growth via the Hippo/YAP pathway.
Han Y, Zhang L, Yu X, Wang S, Xu C, Yin H, Wang S
Cell death & disease 2019 May 10;10(5):374
Cell death & disease 2019 May 10;10(5):374
Modification of α2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway.
Yuan Q, Chen X, Han Y, Lei T, Wu Q, Yu X, Wang L, Fan Z, Wang S
International journal of cancer 2018 Nov 1;143(9):2319-2330
International journal of cancer 2018 Nov 1;143(9):2319-2330
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The ST6GAL1 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human ST6GAL1. This antibody recognizes human, mouse antigen. The ST6GAL1 antibody has been validated for the following applications: ELISA, WB analysis.
